Nanoscope Therapeutics to Set New Standards in Gene Therapy at Advanced Therapies USA 2026
Nanoscope Therapeutics to Participate in Advanced Therapies USA 2026
Nanoscope Therapeutics, known for its innovative approaches to treating retinal degeneration, is set to make significant contributions at the upcoming Advanced Therapies USA 2026 conference. Scheduled for November 4 and 5, 2026, at the Hynes Convention Center in Boston, Massachusetts, this year's event promises to be a pivotal gathering for stakeholders within the cell and gene therapy landscape.
The company’s Co-Founder and CEO, Sulagna Bhattacharya, will join a keynote panel aimed at tackling the evolving challenges and opportunities in the cell and gene therapy sectors. In the session titled "Navigating the Cell and Gene Therapy Landscape: Opportunities and Challenges for Driving Market Success," Ms. Bhattacharya will share insights on how Nanoscope's advancements, particularly the investigational gene therapy MOGENRY® (sonpiretigene isteparvovec; MCO-010), are poised to redefine treatment protocols for patients with inherited retinal diseases.
Additionally, Co-Founder and Chief Scientific Officer, Dr. Samarendra Mohanty, will present his expertise on
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.